WallStSmart
COEP

Coeptis Therapeutics Inc

NASDAQ: COEP · HEALTHCARE · BIOTECHNOLOGY

$16.40
+1.17% today

Updated 2026-04-24

Market cap
$102.06M
P/E ratio
P/S ratio
74.88x
EPS (TTM)
$-2.81
Dividend yield
52W range
$7 – $21
Volume
0.0M

WallStSmart proprietary scores

23
out of 100
Grade: F
Strong Sell
Investment rating
6.3
Growth
B
5.0
Quality
C+
2.5
Profitability
F
6.7
Valuation
B
/9
Piotroski F-Score
Altman Z-Score
Industry rank
View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target
$3.00
-81.71%
12-Month target
Intrinsic (DCF)
$56.80
Margin of safety
+78.89%

Price chart

Stock snapshot

Strengths
+ Revenue growth 1,564.00% QoQ
+ 78.89% below intrinsic value
Risks
- Thin margins at 0.00%
- Negative free cash flow $-1.69M

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$0.00$0.00$0.00$1.36M$1.36M
Net income$-37.57M$-21.27M$-10.88M$-11.92M$-1.58M
EPS$-2.81
Free cash flow$-3.88M$-3.88M$-6.65M$-8.60M$-1.69M
Profit margin-874.29%

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
COEP$102.06M236.32.56.75.0+78.89%Avoid
LLY$948.95B7810.010.05.06.0Strong Buy
JNJ$536.54B594.79.03.36.0-71.41%Buy
ABBV$380.57B634.08.04.05.0-55.64%Buy
UNH$343.21B545.35.54.75.5-26.61%Buy
MRK$285.64B503.38.02.75.0-49.34%Hold

Smart narrative

Coeptis Therapeutics Inc trades at $16.40. Our Smart Value Score of 23/100 indicates the stock is weak. TTM revenue stands at $1.36M. Our DCF model estimates intrinsic value at $56.80.

Frequently asked questions

What is Coeptis Therapeutics Inc's stock price?

Coeptis Therapeutics Inc (COEP) trades at $16.40, on a P/S of 74.9x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.

Is Coeptis Therapeutics Inc overvalued?

Coeptis Therapeutics Inc carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $56.80 versus the $16.40 price, a 78.9% margin of safety on a cash flow basis.

What is the price target of Coeptis Therapeutics Inc (COEP)?

The 12-month analyst consensus target is $3.00, about 81.7% below the current $16.40. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

What is the intrinsic value of Coeptis Therapeutics Inc (COEP)?

Our DCF model estimates intrinsic value at $56.80, a +78.9% margin of safety versus today's $16.40. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.

What is Coeptis Therapeutics Inc's revenue?

Coeptis Therapeutics Inc's trailing twelve-month revenue is $1.36M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio74.88x
ROE-136.90%
Beta-0.43
50D MA$12.26
200D MA$13.58
Shares out0.01B
Float0.01B
Short ratio
Avg volume0.0M

Performance

1 week
1 month
3 months
YTD
1 year
3 years
5 years